Table 2.

Characteristics of patients who received HA-1H TCR-transduced T cells.

Study ID	001	002	003	005	007
Age	51	36	65	47	51
Gender	Female	Female	Female	Female	Male
Disease	Therapy related AML	AML	AML	AML	B-LBL
Cytogenetics/molecular diagnostics	t (9,11) and t (1,15)	NCA	NPM1+ FLT3+	Monosomal karyotype	MLL+ t (4,11)
Number of infusions	2	2	2	2	1
Transplant manipulation	CD34 selection	Alemtuzumab	Alemtuzumab	Alemtuzumab	Alemtuzumab
Stem cell donor	MUD	Sibling	MUD	Sibling	MUD
Conditioning regimen	MA	NMA	NMA	MA	MA
Patient chimerism at first infusion (MNC-leucocytes-granulocytes)	0-0-0	1-1-?	0-0-0	0-0-0	0-0-0
Patient chimerism at second infusion (MNC-leucocytes-granulocytes)	0-0-0	1-1-2	0-0-0	83-77-21
CMV load in serum at first infusion	3.2	0	0	2.5	0
CMV load in serum at second infusion	2.3	0	0	0
Highest detectable CMV load in serum (weeks after first infusion)	4.5 (11)	0	0	2.4 (3)	0
EBV load in serum at first infusion	0	0	0	0	0
EBV load in serum at second infusion	0	0	0	0
Highest detectable EBV load in serum (weeks after first infusion)	0	0	0	0	5.7 (7)
Development of GVHD (weeks after first infusion)	No	No	No	No	No
Infusion of standard care DLI 6 months after alloSCT	No	Yes	Yes	No	No
Adverse events (between first infusion and 6 months post alloSCT)	• Pulmonal aspergillus • Candidaemia • Parvovirus • Bacteriemia • S. Haemolyticus	None	None	Relapse AML	• PTLD • Pulmonal aspergillus
Duration of follow up in weeks after first infusion	19	234	224	19	7
Alive at last follow up	No	Yes	Yes	No	No
Cause of death	Multiple infections			Relapse AML	PTLD

AML, acute myeloid leukemia; B-LBL, B-cell lymphoblastic leukemia; MUD, matched unrelated donor; MA, myelo-ablative; NMA, non-myelo-ablative; PTLD, post-transplant lymphoproliferative disease. NCA, no cytogenetic abnormalities.